Business briefs: Sanofi; Doximity; NYBA

Share this article:

Sanofi named Connect & Coach the winner of its 2013 Data Design Diabetes Innovation Challenge. Connect & Coach entered its hybrid clinical and consumer application for use in retail supermarket or pharmacy settings by registered dietitians and certified diabetes educators to help educate the diabetes community. The firm will take home a grand prize of $100,000 to help develop its idea. Finalists included AllazoEngine, meant to anticipate which patients will be non-adherent and what interventions might keep them on medication; GoCap, a replacement pen cap for prefilled insulin pens that reads dose amounts and times and communicates that info wirelessly, via Bluetooth; MediSapien, which translates raw health data into useful healthcare analytics; and Nuduro, which provides home and on-the-go meal recommendations matched to patient taste and lifestyle as well as nutritional needs. 

Doximity is collaborating with US News & World Report on a free online directory of more than 700,000 practicing US physicians. The deal adds to the publisher's stable of healthcare directories, which include Best Hospitals, Best Medical Schools and Best Health Insurance Plans guides, and gives Doximity, which counts 170,000 physicians as members, a means of enticing doctors to sign up and fill out profiles.

The New York Biotechnology Association has rebranded as NewYorkBIO. The new identity reflects the trade group's maturation from a small, biotech-specific association to one representing over 250 member orgs ranging from therapeutics to devices and diagnostics to genetically modified crop developers. “The evolution of the Association's identity is representative of our expanded mission and responsibility to the New York life sciences community,” said chairman Robert Easton. “Over the past two decades, our membership's demographics and needs have changed and matured. Our new identity as NewYorkBIO not only responds directly to this maturation but also more clearly and fully aligns us with BIO, the national Biotechnology Industry Organization.”

Share this article:

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.